 Canaccord Genuity TSX:CF, LSE:CF analysts have reiterated a Buy rating and issued an 11 price target for Zynerba Pharmaceuticals NASDAQ:ZYNE Inc in a note to clients. The brokerage firm recently hosted Zynerba CEO Armando Anido and CFO Jim Fickenscher at its Canaccord Genuity TSX:CF, LSE:CF Growth Conference in Boston. 